Sandu Pharmaceuticals Quarterly Results
Sandu Pharmaceuticals quarterly results. In Mar 2025, Sandu Pharmaceuticals (SANDUPHQ) reported revenue ₹14 Cr and net profit ₹0 Cr — revenue -12.5% YoY. For annual financials, live price and key ratios, visit SANDUPHQ share price.
SANDUPHQ Quarterly Results — Revenue, Profit & EPS Highlights
Sandu Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review SANDUPHQ earnings valuation to evaluate earnings-based valuation against sector peers.
- Revenue of ₹14 Cr in Mar 2025 (-22.2% vs Sept 2024, -12.5% vs Mar 2024)
- EBITDA of ₹1 Cr in Mar 2025 (+0.0% vs Sept 2024)
- Operating Margin of 3.0% in Mar 2025 (-2.0pp vs Sept 2024)
- Earnings Per Share of ₹0.34 in Mar 2025 (-82.6% vs Sept 2024)
Sandu Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SANDUPHQ quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 18 | 16 | 17 | 18 | -22.2% | -12.5% |
| Net Profit (₹ Cr) | 0 | 1 | 1 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 1 | 1 | 1 | 0 | 1 | - | - |
| EPS (₹) | 0.34 | 1.95 | 0.62 | 0.17 | 0.57 | - | - |
| Operating Margin (%) | 3.0% | 5.0% | 4.0% | 2.0% | 5.0% | - | - |
SANDUPHQ Share Price Trend — 1-Year Movement Across Quarterly Results
Sandu Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check Sandu Pharmaceuticals marketcap in USD to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SANDUPHQ vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sandu Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores